STARPHARMA-HOLDINGS-LTD
28.10.2016 05:21:29 CEST | Business Wire | Press release
Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced the allowance of a patent by the US Patent Office for a Priostar® glyphosate formulation. The patent’s term is expected to be to 2030 providing an extension over existing granted Priostar® patents. Additional term may also be available in relation to patent office delay and regulatory approval.
This patent adds further value to the Priostar® patent portfolio which comprises granted patents in key markets, including in the US, Europe, and China. This patent will extend the value of the Priostar® glyphosate product opportunity for both Starpharma and its partners.
Priostar® -enhanced glyphosate formulations have been shown to deliver improved weed control capabilities compared to standard marketed formulations of glyphosate, particularly in hard to kill weeds. The enhanced formulations have also shown faster knock-down of weeds.
Glyphosate (the active ingredient in Roundup® ) is the world’s most widely used herbicide with 2014 global market sales of US$5.7B(1) and is expected to grow to US$8.8B by 2019(2) . In the United States, glyphosate is the leading herbicide for the control of weeds on maize, soybean and cotton crops, making it one of the most widely used herbicides. It is also used in agriculture and forestry, on lawns and gardens, and for weeds in industrial areas.
Starpharma has Priostar® partnerships with a number of global partners to enhance agricultural formulations, including with Adama for a Priostar® improved 2,4-D formulation for the US market.
Starpharma Chief Executive, Dr Jackie Fairley, commented: “This development for our glyphosate Priostar® patent portfolio is a valuable commercial achievement and confirmation of the innovation that Priostar® brings to crop protection products. We continue to work in partnership with leading agrochemical companies across the globe to develop innovative, proprietary Priostar® formulations that improve product performance and deliver benefits to farmers.”
(1)
Phillips McDougall Industry Overview 2015.
(2)
Transparency
Market Research 2014.
About Starpharma
Starpharma
Holdings Limited, located in Melbourne Australia, is an ASX 300 company
and is a world leader in the development of dendrimer products for
pharmaceutical, life science and other applications.
For more information please visit: www.starpharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007030/en/
Contact:
Media:
WE Buchan
Rebecca Wilson
Mob:
+61-417-382-391
rwilson@buchanwe.com.au
or
Starpharma:
Dr
Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and
Company Secretary
+61-3-8532-2704
investor.relations@starpharma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Celebrates International Women’s Day by Spotlighting Women in Games and Advancing Its Vision for Female Leadership8.3.2026 14:00:00 CET | Press release
Accelerating Representation, Influence, And Leadership For Women Across The Gaming Industry Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today reaffirmed its ongoing commitment to supporting women across the global gaming ecosystem through curated community initiatives, industry events, and thought leadership platforms in key growth markets, including Türkiye, Dubai, and Cyprus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308595758/en/ Graphic: Xsolla As the gaming industry continues to expand across emerging and high-growth markets, Xsolla is focused on empowering developers globally, including fostering a more inclusive ecosystem that gives women founders, studio leaders, publishers, and entrepreneurs greater access to visibility, networks, and opportunities. Through a series of targeted industry gatherings and community-led discussions, Xsolla has activel
Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 20268.3.2026 09:00:00 CET | Press release
From system-level software to end-to-end solutions, Aqara demonstrates how intelligent spaces are designed, operated, and scaled. Aqara, a global leader and pioneer in IoT, today unveiled its cutting-edge innovations in intelligent space technology at Light + Building 2026 (Hall 9.0, Booth A50). Aqara’s demonstration offers a glimpse into a comprehensive system that offers intelligent lighting control, energy saving, and space security experience for professional usage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308903989/en/ Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 2026 System-level Intelligent Control Aqara introduces a centralized system solution designed to streamline the management of building deployments at any scale. Moving beyond individual device control, Aqara offers a unified solution that provides architects, facility managers, and developers with
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom